Three patients with distinct forms of autoimmune encephalitis—anti-GABABR, anti-LGI1, and anti-NMDAR encephalitis—demonstrated rapid and sustained clinical improvement following efgartigimod treatment. Here, LGI1 is linked to autoimmune encephalitis.